Lenvatinib shows potential in advanced liver cancer

Lenvatinib may become a potential therapeutic option for patients with advanced hepatocellular carcinoma (HCC), the results of phase I/II clinical trial suggest.

Hepatocellular carcinoma: potential treatment identified (photo: SPL)
Hepatocellular carcinoma: potential treatment identified (photo: SPL)

The findings were presented at the 2012 meeting of the European Society of Medical Oncology in Vienna this month.

Lenvatinib, an orally active inhibitor of multiple receptor tyrosine kinases (RTKs) involved in angiogenesis and tumour proliferation, is being investigated for the treatment of recurrent glioblastoma and in combination with everolimus in metastatic renal carcinoma.

The scope of the phase I/II clinical trial was to establish the safety and efficacy of lenvatinib in patients with advanced HCC.

Forty-six patients were enrolled in the trial; they may have had prior treatment for their HCC including sorafenib. The starting dose of lenvatinib was 12mg once daily in 28 days cycles until disease progression or progression of unmanageable toxicities.

The researchers observed that 76% patients required dose adjustments for the management of toxicities (hypertension, palmo-plantar erythrodysaesthesia syndrome, anorexia, proteinuria, fatigue and thrombocytopenia).

They concluded that, although in this study there were no new toxicities associated with TKI class, a weight-based starting dose of 8mg once daily for patients weighing under 60kg may be needed to minimise toxicity while maintaining the 12mg once daily for patients weighing over 60kg.

The median time to progression (TTP) is 7.49 months (95% CI:5.45-9.43) and media overall survival is 13.9 months (95% CI:11.8-).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

NHS sign outside a building

PCN contract overhaul defers two-week appointment target until April 2023

NHS England has announced changes to the network contract DES, including deferring...


NHS sets out priorities for extra GP funding this winter

Integrated care boards could target extra funding for general practice at phone systems,...

Shadow chancellor Rachel Reeves

Labour promises to double medical school places with tax cut reversal

A Labour government would double medical school places with funding raised from reversing...

What is GP Connect?

GP Connect articles are provided and funded by a selection of GPonline's partners...

Gas meter

BMA and local NHS leaders scramble to support GPs facing rising costs

Spiralling energy costs have forced local NHS leaders to draw up emergency support...

Health and social care secretary and deputy prime minister Therese Coffey

What does the government's 'plan for patients' mean for general practice?

Health and social care secretary Therese Coffey has unveiled the government's new...